EU Signs Deal with GSK for Supply of COVID Potential Drug

Updated : Jul 28, 2021, 12:08 UTC1min read
BRUSSELS (Reuters) – The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday.
Most Popular

The contract has been signed by 16 of the 27 EU states. The drug, which is being assessed by the EU medicines regulator and is not authorized yet, can be used for the treatment of coronavirus patients with mild symptoms who do not require supplemental oxygen, the Commission said.

(Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)

Advertisement
Know where Markets is headed? Take advantage now with

Your capital is at risk

Don't miss a thing! Sign up for a daily update delivered to your inbox

Latest Articles

See All